Zobrazeno 1 - 10 of 44 pro vyhledávání: '"S.K. Mok"'
1
Akademický článek
Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease
Autor: Molly S.C. Li, M.B.B.S., Kirsty W.C. Lee, MBChB, Kevin K.S. Mok, MBChB, Herbert H.F. Loong, M.B.B.S., K.C. Lam, MBChB, Florence S.T. Mok, M.B.B.S., Landon L. Chan, MBChB, Y.M. Lau, M.B.B.S., K.P. Chan, MBChB, Joyce T.Y. Ng, MBChB, Wesley K.Y. Wong, M.B.B.S., Benjamin H.W. Lam, M.B.B.S., Allen C.C. Chen, BM, Matthew M.P. Lee, MBChB, Olivia H. Chen, MD, PhD, Tony S.K. Mok, MD
Publikováno v: JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100648- (2024)
Introduction: Interstitial lung disease (ILD) is the most frequent cause of drug-related mortality from EGFR tyrosine kinase inhibitors (TKIs). Yet, for patients with symptomatic osimertinib-induced ILD, the risk of recurrent ILD associated with EGFR
Externí odkaz: https://doaj.org/article/3e7352949ccd4e5d8d2933a594642014
Zobrazit plný text záznamu
2
Akademický článek
Clinical application of liquid biopsy genomic profiling in NSCLC: Asian perspectives
Autor: Molly S.C. Li, Kevin K.S. Mok, Landon L. Chan, Tony S.K. Mok
Publikováno v: The Journal of Liquid Biopsy, Vol 3, Iss , Pp 100131- (2024)
Molecular profiling is essential for treatment of patients with advanced non-small cell lung cancer. Extensive evidence supports the clinical application of liquid biopsy in molecular profiling and thus has been incorporated into multiple internation
Externí odkaz: https://doaj.org/article/ea7cb5082ad1433a842e674d1fbbba18
Zobrazit plný text záznamu
3
Akademický článek
Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042
Autor: Aaron S. Mansfield, MD, Roy S. Herbst, MD, PhD, Gilberto de Castro, Jr., MD, PhD, Rina Hui, MB, BS, PhD, Nir Peled, MD, PhD, Dong-Wan Kim, MD, Silvia Novello, MD, PhD, Miyako Satouchi, MD, Yi-Long Wu, MD, Edward B. Garon, MD, Martin Reck, MD, PhD, Andrew G. Robinson, MD, Ayman Samkari, MD, Bilal Piperdi, MD, Victoria Ebiana, MD, Jianxin Lin, MS, Tony S.K. Mok, MD
Publikováno v: JTO Clinical and Research Reports, Vol 2, Iss 8, Pp 100205- (2021)
Introduction: We retrospectively evaluated outcomes in patients with programmed death-ligand 1 (PD-L1)–positive non–small-cell lung cancer (NSCLC) to determine whether baseline (i.e., at study enrollment) brain metastases were associated with the
Externí odkaz: https://doaj.org/article/4253c840bb3a4ea2a990a5ad8dd55f52
Zobrazit plný text záznamu
4
Akademický článek
Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial
Autor: James Chih-Hsin Yang, MD, PhD, Tony S.K. Mok, MD, Shun Lu, MD, Kazuhiko Nakagawa, MD, PhD, Nobuyuki Yamamoto, MD, Yuan-Kai Shi, MD, Li Zhang, MD, Ross A. Soo, M.B.B.S., PhD, Satoshi Morita, PhD, Tomohide Tamura, MD
Publikováno v: JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100142- (2021)
Introduction: Despite recent advances in NSCLC treatment, specific data on the elderly population remain limited. In this post hoc subgroup analysis of the East Asia S-1 Trial in Lung Cancer (EAST-LC) trial, we compared S-1 and docetaxel (DTX) in pat
Externí odkaz: https://doaj.org/article/789f40ff2e624800b8f722aef5b2ae98
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje